ARWR — Arrowhead Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.06bn
- $2.85bn
- $240.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.08 | ||
| Price to Tang. Book | 20.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.22% | ||
| Return on Equity | -110.45% | ||
| Operating Margin | -164.75% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 168.8 | 87.99 | 138.29 | 243.23 | 240.74 | 139.03 | 157.94 | 71.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Directors
- Douglass Given CHM (69)
- Christopher Anzalone CEO (52)
- Kenneth Myszkowski CFO (55)
- James Hamilton SVP (44)
- Patrick O'Brien CCO (58)
- Javier San Martin OTH (56)
- Michael Perry LED (62)
- Marianne De Backer IND (53)
- Mauro Ferrari IND (62)
- Adeoye Olukotun IND (77)
- William Waddill IND (64)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 13th, 2001
- Public Since
- December 14th, 1993
- No. of Shareholders
- 97
- No. of Employees
- 525
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 123,896,914
- Address
- 177 E Colorado Blvd, Suite 700, PASADENA, 91105
- Web
- https://arrowheadpharma.com/
- Phone
- +1 6266964702
- Contact
- Vincent Anzalone
- Auditors
- Rose, Snyder & Jacobs
Upcoming Events for ARWR
Q3 2024 Arrowhead Pharmaceuticals Inc Earnings Release
Similar to ARWR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Arrowhead Pharmaceuticals share price?
As of Today at 19:02 UTC, shares in Arrowhead Pharmaceuticals are trading at $24.70. This share price information is delayed by 15 minutes.
How has the Arrowhead Pharmaceuticals share price performed this year?
Shares in Arrowhead Pharmaceuticals last closed at $24.70 and the price had moved by -19.02% over the past 365 days. In terms of relative price strength the Arrowhead Pharmaceuticals share price has underperformed the S&P500 Index by -34.6% over the past year.
What are the analyst and broker recommendations for Arrowhead Pharmaceuticals?
The overall consensus recommendation for Arrowhead Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Arrowhead Pharmaceuticals dividend yield?
Arrowhead Pharmaceuticals does not currently pay a dividend.
Does Arrowhead Pharmaceuticals pay a dividend?
Arrowhead Pharmaceuticals does not currently pay a dividend.
When does Arrowhead Pharmaceuticals next pay dividends?
Arrowhead Pharmaceuticals does not currently pay a dividend.
How do I buy Arrowhead Pharmaceuticals shares?
To buy shares in Arrowhead Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arrowhead Pharmaceuticals?
As of the previous close price of $24.70, shares in Arrowhead Pharmaceuticals had a market capitalisation of $3.06bn.
Where are Arrowhead Pharmaceuticals shares listed?
Here are the trading details for Arrowhead Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARWR
What kind of share is Arrowhead Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Arrowhead Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arrowhead Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Arrowhead Pharmaceuticals is $55.38. That is 124.21% above the last closing price of $24.70.
Analysts covering Arrowhead Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.67 for the next financial year.
What is the trend in the Arrowhead Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arrowhead Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -20.73%.
As of the last closing price of $24.70, shares in Arrowhead Pharmaceuticals were trading -16.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arrowhead Pharmaceuticals PE Ratio?
The Arrowhead Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' management team is headed by:
- Douglass Given - CHM
- Christopher Anzalone - CEO
- Kenneth Myszkowski - CFO
- James Hamilton - SVP
- Patrick O'Brien - CCO
- Javier San Martin - OTH
- Michael Perry - LED
- Marianne De Backer - IND
- Mauro Ferrari - IND
- Adeoye Olukotun - IND
- William Waddill - IND